<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772590</url>
  </required_header>
  <id_info>
    <org_study_id>NCHECR-CORAL 1</org_study_id>
    <nct_id>NCT00772590</nct_id>
  </id_info>
  <brief_title>Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response</brief_title>
  <acronym>CORAL</acronym>
  <official_title>Randomised Double-blind Placebo Controlled Study to Measure the Effect of Antiretroviral Therapy (ART) Intensification With Raltegravir and/or Hyper-immune Bovine Colostrum on CD4+ T Cell Count in ART Treated, HIV-1 Infected Individuals With Suboptimal CD4+ T Cell Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study to measure the effect on CD4 counts of adding to current anti-retroviral
      regimen raltegravir with or without hyper-immune bovine colostrum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to measure the effect on CD4+ T cell outcome as
      measured by the mean time weighted CD4+ T cell count change over 24 weeks of two
      interventions: (I) cART intensification with raltegravir and (II) cART combined with
      hyper-immune bovine colostrum in HIV-1 infected individuals who have failed to achieve a
      CD4+ T cell count greater than 350 cells/µL despite persistent HIV plasma viraemia below 50
      copies/mL on cART.

      Eligible patients will be randomised to one of four arms. I. Raltegravir + hyper-immune
      bovine colostrum placebo II. Raltegravir placebo + hyper-immune bovine colostrum III.
      Raltegravir + hyper-immune bovine colostrum IV. Raltegravir placebo + hyper-immune bovine
      colostrum placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change From Baseline CD4+ Cell Count</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of normalised mean change from baseline CD4+ cell count</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir, bovine colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir and hyper-immune bovine colostrum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyper-immune bovine colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyper-immune bovine colostrum and Raltegravir placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir and Hyper-immune Bovine Colostrum Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Raltegravir placebo and hyper-immune bovine colostrum placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>Tablets, 400mg, twice daily</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyper-immune Bovine Colostrum</intervention_name>
    <description>Tablet, 1800mg, twice daily</description>
    <arm_group_label>Hyper-immune bovine colostrum</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>raltegravir placebo</intervention_name>
    <description>One tablet, twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyper-immune Bovine Colostrum placebo</intervention_name>
    <description>Three tablets twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir and hyper-immune bovine colostrum</intervention_name>
    <description>400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum</description>
    <arm_group_label>Raltegravir, bovine colostrum</arm_group_label>
    <other_name>Raltegravir + hyper-immune bovine colostrum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  Age &gt;18 years

          -  Signed informed consent

          -  Receiving combination ART (cART) for at least 12 months with a stable cART regimen
             for a minimum of 6 months. A formulation change or modification of dosage schedule is
             acceptable (for example ritonavir - boosted lopinavir capsules for tablets, abacavir
             (ABC) or tenofovir (TDF) and lamivudine (3TC) or emtricitabine (FTC) as single agents
             for ABC/3TC or TDF/FTC fixed dose combinations)

          -  Two consecutive plasma HIV RNA viral load measurements &lt;50 (or &lt;400 copies/mL
             depending upon lowest level of detection of the local assay) in the 9 months
             preceding the screening visit. A single isolated HIV RNA viral load &gt;50 (or &gt;400)
             copies/mL will not exclude the patient provided the viral load result &gt;50 (or 400)
             copies/mL on therapy follows a previous result &lt;50 (or 400) copies/mL, and there is a
             follow-up result &lt;50 copies/mL at least one week following the &gt;50 (or 400) copies/mL
             reading in the absence of a change to any component of the ART regimen.

          -  CD4+ T cell count &lt;350 cells/µL throughout the 6 months preceding the screening visit
             with &lt;50 cells/µL increase in the last 12 months

        Exclusion Criteria:

          -  Receiving a cART regimen containing an integrase inhibitor

          -  Anticipated change of cART in the 24 weeks following randomisation

          -  Participating in study with an investigational compound or device within 30 days of
             signing informed consent

          -  Use of immune modulating therapies or immunosuppressive medications within 60 days
             prior to study entry. Patients using inhaled or nasal steroids are not excluded

          -  Pregnant or breastfeeding woman

          -  Cow's milk allergy

          -  Concurrent treatment with phenobarbitol, phenytoin or rifampicin.

          -  A known cause of impaired CD4+ T cell gain: for example, patients with splenomegaly
             or individuals whose current cART regimen contains both tenofovir and didanosine
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean Emery, BSc (Hons), PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre in HIV Epidemiology and Clinical Research, University of New South Wales</affiliation>
  </overall_official>
  <results_reference>
    <citation>Byakwaga H, Kelly M, Purcell DF, French MA, Amin J, Lewin SR, Haskelberg H, Kelleher AD, Garsia R, Boyd MA, Cooper DA, Emery S; CORAL Study Group. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis. 2011 Nov 15;204(10):1532-40. doi: 10.1093/infdis/jir559. Epub 2011 Sep 19.</citation>
    <PMID>21930607</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 23, 2012</lastchanged_date>
  <firstreceived_date>October 14, 2008</firstreceived_date>
  <firstreceived_results_date>May 6, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>antiretroviral therapy intensification</keyword>
  <keyword>suboptimal CD4+ T cell response</keyword>
  <keyword>virological suppression</keyword>
  <keyword>bovine colostrum</keyword>
  <keyword>raltegravir</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <recruitment_details>100 patients were screening at 20 clinical sites in Australia</recruitment_details>
      <pre_assignment_details>25 of 100 patients screened did not meet study inclusion criteria and were excluded from study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir + Hyper-immune Bovine Colostrum</title>
          <description>Raltegravir and hyper-immune bovine colostrum</description>
        </group>
        <group group_id="P2">
          <title>Hyper-immune Bovine Colostrum</title>
          <description>Hyper-immune bovine colostrum and Raltegravir placebo</description>
        </group>
        <group group_id="P3">
          <title>Raltegravir</title>
          <description>Raltegravir and Hyper-immune Bovine Colostrum placebo</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Raltegravir placebo and hyper-immune bovine colostrum placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir + Hyper-immune Bovine Colostrum</title>
          <description>Raltegravir and hyper-immune bovine colostrum</description>
        </group>
        <group group_id="B2">
          <title>Hyper-immune Bovine Colostrum</title>
          <description>Hyper-immune bovine colostrum and Raltegravir placebo</description>
        </group>
        <group group_id="B3">
          <title>Raltegravir</title>
          <description>Raltegravir and Hyper-immune Bovine Colostrum placebo</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Raltegravir placebo and hyper-immune bovine colostrum placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="17"/>
                <measurement group_id="B5" value="73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="17"/>
                <measurement group_id="B4" value="16"/>
                <measurement group_id="B5" value="69"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52" spread="11"/>
                <measurement group_id="B2" value="56" spread="9"/>
                <measurement group_id="B3" value="50" spread="10"/>
                <measurement group_id="B4" value="55" spread="10"/>
                <measurement group_id="B5" value="53" spread="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="16"/>
                <measurement group_id="B5" value="69"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="18"/>
                <measurement group_id="B4" value="17"/>
                <measurement group_id="B5" value="73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline CD4+ Cell Count</title>
        <description>Comparison of normalised mean change from baseline CD4+ cell count</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>intention to treat (ITT) - all randomised patients who commenced randomly assigned therapy and who had at least one on-study visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir + Hyper-immune Bovine Colostrum</title>
            <description>Raltegravir and hyper-immune bovine colostrum</description>
          </group>
          <group group_id="O2">
            <title>Hyper-immune Bovine Colostrum</title>
            <description>Hyper-immune bovine colostrum and Raltegravir placebo</description>
          </group>
          <group group_id="O3">
            <title>Raltegravir</title>
            <description>Raltegravir and Hyper-immune Bovine Colostrum placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Raltegravir placebo and hyper-immune bovine colostrum placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="18"/>
                  <measurement group_id="O4" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline CD4+ Cell Count</title>
            <description>Comparison of normalised mean change from baseline CD4+ cell count</description>
            <units>Cells/microlitre</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.62" spread="32.19"/>
                  <measurement group_id="O2" value="2.68" spread="35.8"/>
                  <measurement group_id="O3" value="8.68" spread="44.58"/>
                  <measurement group_id="O4" value="21.87" spread="34.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.01</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to week 24</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir + Hyper-immune Bovine Colostrum</title>
          <description>Raltegravir and hyper-immune bovine colostrum</description>
        </group>
        <group group_id="E2">
          <title>Hyper-immune Bovine Colostrum</title>
          <description>Hyper-immune bovine colostrum and Raltegravir placebo</description>
        </group>
        <group group_id="E3">
          <title>Raltegravir</title>
          <description>Raltegravir and Hyper-immune Bovine Colostrum placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Raltegravir placebo and hyper-immune bovine colostrum placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hosp. for chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hosp. for possible Influenza A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hosp. For cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Effect of interventions only measured in peripheral blood</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sean Emery</name_or_title>
      <organization>Kirby Institute, University of New South Wales</organization>
      <phone>+612 938509900</phone>
      <email>semery@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
